The acquisition, which involves a concurrent licensing deal with startup Mirador, gives Jasper a chance to rebound from setbacks that have wiped out most of its market value.
Source: BioPharma Dive
You may also like
KRAS-Targeted Vaccine Crosses First Clinical Milestone...
Gene Therapy Partners Aim to Enhance Protein Expression
Modular Antibody–ADC Click Chemistry Overcomes Tumor...
See, Blind Mice: Consortium’s Drugs Restore Sight
Genetic Study Links Excessive Sweating to Neurological...
Parkinson’s in the Clinic, Insilico enters Phase...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.